Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0800
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2641
    +0.0019 (+0.15%)
     
  • USD/JPY

    151.2160
    -0.1560 (-0.10%)
     
  • Bitcoin USD

    70,402.98
    -920.28 (-1.29%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Is Good News Enough for You to Buy NGM on the Dip?

Is Good News Enough for You to Buy NGM on the Dip?

If revenue is not yet being generated from products, a company's stock price can rely heavily on positive news from treatment candidates moving through clinical trials. NGM Biopharmaceuticals (NASDAQ: NGM) has had a few ups and downs in its clinical trials in 2021, leading to fluctuations in stock price. Does NGM have what it takes to go the distance?

Advertisement